Related Experiment Video
Updated: Apr 30, 2026
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
PLCε1: a potential target of RNA interference therapy for gastric cancer
1Department of Oncology, Changhai Hospital, Secondary Military Medical University, Shanghai 200240, PR China.
Abstract:
Phospholipase C epsilon 1 (PLCε1) has been recently identified as a novel potential biomarker for gastric cancer because of its critical role in inflammation and tumorigenesis. Until now, there are no further reports to investigate the feasibility of gene therapy by suppressing PLCε1 expression for gastric cancer. In this study, a small interfering RNA (shRNA) targeting PLCε1 was firstly transfected into gastric cancer cells in order to silence PLCε1 expression. Both mRNA and protein expression of PLCε1 in gastric cancer cells significantly reduced by RT-PCR and Western blotting analysis. Moreover, subsequent results revealed that PLCε1 shRNA depressed the in vitro and in vivo growth of gastric cancer cells by using MTT assay and tumor xenograft experiment. Furthermore, after PLCε1 shRNA transfection, the expression of proinflammatory molecules including tumor necrosis factor-α (TNF-α), cyclooxygenase 2 (COX-2), interleukin (IL)-6 and chemokine (C-X-C motif) ligand (CXCL)-1 were unaffected, but only chemokine (C-C motif) ligand (CCL)-2 expression decreased in the gastric cancer cells. It is implied that PLCε1 may inhibit the growth of gastric cancer cells via CCL-2 protein mediated pathway. These results suggest that PLCε1 might be an alternative molecular target for gastric cancer gene therapy.
Insights
Gene therapy targeting Phospholipase C epsilon 1 (PLCε1) shows promise for gastric cancer. Suppressing PLCε1 with shRNA reduced tumor growth and may involve the CCL-2 pathway.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Phospholipase C epsilon 1 (PLCε1) is implicated in gastric cancer inflammation and tumorigenesis.
- PLCε1 is a potential novel biomarker for gastric cancer.
- The feasibility of gene therapy targeting PLCε1 in gastric cancer remains unexplored.
Purpose of the Study:
- To investigate the efficacy of gene therapy using small interfering RNA (shRNA) to suppress PLCε1 expression in gastric cancer cells.
- To evaluate the impact of PLCε1 suppression on gastric cancer cell growth both in vitro and in vivo.
- To explore the molecular mechanisms underlying PLCε1's role in gastric cancer, specifically its relationship with inflammatory markers.
Main Methods:
- Gastric cancer cells were transfected with PLCε1-targeting shRNA.
- Quantitative reverse transcription PCR (RT-PCR) and Western blotting were used to assess PLCε1 mRNA and protein levels.
- In vitro cell proliferation was measured using MTT assays.
- In vivo tumor growth was evaluated using tumor xenograft models.
- Expression levels of inflammatory molecules (TNF-α, COX-2, IL-6, CXCL-1, CCL-2) were analyzed post-shRNA transfection.
Main Results:
- PLCε1 shRNA significantly reduced both mRNA and protein expression of PLCε1 in gastric cancer cells.
- Suppression of PLCε1 by shRNA inhibited the in vitro and in vivo growth of gastric cancer cells.
- While most tested proinflammatory molecules remained unaffected, PLCε1 shRNA transfection led to a decrease in chemokine (C-C motif) ligand (CCL)-2 expression.
- PLCε1 may inhibit gastric cancer cell growth through a pathway mediated by CCL-2.
Conclusions:
- Gene therapy targeting PLCε1 using shRNA is a feasible approach for suppressing its expression in gastric cancer.
- Suppression of PLCε1 effectively inhibits gastric cancer cell proliferation and tumor growth.
- PLCε1 may play a role in gastric cancer progression via the CCL-2 pathway, suggesting PLCε1 as a potential therapeutic target.
Related Concept Videos
02:15Experimental RNAi
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:23RNA Interference
02:39lncRNA - Long Non-coding RNAs
01:23Types of RNA
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...